Our Knowledge
Network
Leveraging the breadth and depth of industry knowledge gained through the work in our Innovation Hub, we are able to connect the dots in a way others don't see
Research.
Analyze.
Synthesize.
Is Women's Health reaching an inflection point?
x
x
PharmaPhorum
x
xx
x
x
x
x
PharmaPhorum provided an overview of the key themes from Weatherden's Women’s Health: From Intractable to Investable Symposium, exploring how better patient stratification, evidence generation and clinical development strategies could unlock innovation in Women's Health. Click the link to read more.
Women's Health: From Intractable to Investable
x
x
Philippa Egerton-Warburton
VP Head of Business Development
Laurel Woodridge PhD
Strategy & Data Science Consultant
Weatherden convened leaders from across the biotech pharma, investment and academic ecosystem to explore how smarter clinical development and regulatory strategy can unlock the next wave of innovation in Women’s Health.
When to use a
'no regret' dose?
x
x
Simon Hutchings PhD
VP Head of Clinical Pharmacology
x
x
x
x
One of the most important decisions in early development is whether to back a single “no-regret” dose or generate evidence across multiple doses first. Simon discusses how dose strategy shapes interpretability, regulatory confidence, and program risk, with examples from Alzheimer’s disease,
oncology, and adaptive trial design.
News article
x
x
Optimum
x
Text to come
Dose Matters: Navigating FDA Guidance for Oncology Drug Development
x
Michael Grant MD
VP Clinical Development
Simon Hutchings PhD
VP Head of Clinical Pharmacology
x
In collaboration with Physiomics, we discuss how the FDA has been engaging with drug developers to reform how dose optimization is approached
for new cancer drugs.
Decoding clinical
trial statistics
x
x
Margaret Jones PhD
VP Head of Statistics
Andy Grieve PhD
Independent Consultant
x
x
x
Strategy Analyst Alex Girling interviews Margaret
and Andy to pick their brains on the benefits of overcoming resistance to Bayesian methods, data-driven development plans and adaptive trials.
From Intractable to Investable: Rethinking Clinical Development in Women's Health
x
Laurel Woodridge (PhD)
Strategy & Data Science Consultantx
Following the success of our Women's Health symposium: From Intractable to Investable, Laurel writes about the key takeaways from the discussion and how successful development strategies from other therapuetic areas can be translated to Women's Health conditions.
Expert opinion: Navigating the challenges in the clinical trials sector
x
Drug Discovery World
x
On International Clinical Trials Day, Kirsty Wydenbach (MD) and Michael Grant (MD) spoke with DDW about the current state of play within global clinical trials.
Rethinking Progress in Clinical Trials
x
x
The Medicine Maker
x
x
x
To mark International Clinical Trials Day, Co-founder Duncan McHale (MD, PhD) sat down with The Medicine Maker to discuss the early signals they trust, the growing importance of translational and adaptive trial design, shifting regulatory expectations, and why trust, inclusion, and operational discipline are now central to ethical research and high-quality data.
Women's Health: From Intractable to Investable
x
x
Philippa Egerton-Warburton
VP Head of Business Development
Laurel Woodridge PhD
Strategy Consultant
Weatherden is convening leaders from across the biotech pharma, investment and academic ecosystem to explore how smarter clinical development and regulatory strategy can unlock the next wave of innovation in women’s health.
When to use a
'no regret' dose?
x
x
Simon Hutchings PhD
VP Head of Clinical Pharmacology
x
x
x
One of the most important decisions in early development is whether to back a single “no-regret” dose or generate evidence across multiple doses first. Simon discusses how dose strategy shapes interpretability, regulatory confidence, and program risk, with examples from Alzheimer’s disease,
oncology, and adaptive trial design.
Dose Matters: Navigating FDA Guidance for Oncology Drug Development
x
Michael Grant MD
VP Clinical Development
Simon Hutchings PhD
VP Head of Clinical Pharmacology
x
In collaboration with Physiomics, we discuss how the FDA has been engaging with drug developers to reform how dose optimization is approached
for new cancer drugs.
Weatherden Insights
The cross-functional nature of work required to fully tackle the difficult problems in drug development provides us with unique insights - spotting patterns and ways to innovate
Our team generates insights and thought leadership based on what they are seeing now and over time